Cited by 143CAR-T cell therapy researchImmunotherapy and Immune ResponsesBacterial Cancer Therapy

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases

Open access

Magee, Michael S., Abraham, Tara S., Baybutt, Trevor R., Flickinger, John C., Ridge, Natalie A., Marszalowicz, Glen P., Prajapati, Priyanka, Hersperger, Adam R., Waldman, Scott A., Snook, Adam E.·2018·Cancer Immunology Research

DOI 10.1158/2326-6066.cir-16-0362PMC PMC5932207

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Abstract One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs. Previous work has demonstrated that T cells engineered to express chimeric antigen receptors (CAR-T cells) targeting the murine homolog of the colorectal cancer antigen GUCY2C treat established colorectal cancer metastases, without toxicity to the normal GUCY2C-expressing intestinal epithelium, reflecting structural compartmentalization of endogenous GUCY2C to apical membranes comprising the intestinal lumen. Here, we examined the utility of a human-specific, GUCY2C-directed single-chain variable fragment as the basis for a CAR construct targeting human GUCY2C-expressing metastases. Human GUCY2C-targeted murine CAR-T cells promoted antigen-dependent T-cell activation quantified by activation marker upregulation, cytokine production, and killing of GUCY2C-expressing, but not GUCY2C-deficient, cancer cells in vitro. GUCY2C CAR-T cells provided long-term protection against lung metastases of murine colorectal cancer cells engineered to express human GUCY2C in a syngeneic mouse model. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C, providing durable survival in a human xenograft model in immunodeficient mice. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer. Cancer Immunol Res; 6(5); 509–16. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0362

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Human Lymphoid and Myeloid Cell Development in NOD/LtSz- scid IL2R γ null Mice Engrafted with Mobilized Human Hemopoietic Stem Cells,
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,781
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,174
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 880
Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 583

Show all 31 references

Sorted by citations

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
Martinez, M. C., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 865
Metastatic colorectal cancer: mechanisms and emerging therapeutics
Shin, A. E., Giancotti, F. G., & Rustgi, A. K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.01.003 · Cited by 717
CAR T cells in solid tumors: challenges and opportunities
Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02128-1 · Cited by 582
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 470
Adoptive cellular therapies: the current landscape
Rohaan, M. W., Wilgenhof, S., & Haanen, J. B. A. G. (2018) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-018-2484-0 · Cited by 422
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Advances in immunotherapy for colorectal cancer: a review
Golshani, G. M., & Zhang, Y. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820917527 · Cited by 252
LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription
Xiu, B., Chi, Y., Liu, L., Chi, W., Zhang, Q., Chen, J., Guo, R., Si, J., Li, L., Xue, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1115-y · Cited by 213
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 170
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 163
Current status of immunotherapy in metastatic colorectal cancer
Wróbel, P., & Ahmed, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3202-8 · Cited by 144
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 139
Reactions Related to CAR-T Cell Therapy
Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663201 · Cited by 129
Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Edeline, J., Houot, R., Marabelle, A., & Alcantara, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01067-5 · Cited by 115
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 116
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
Feng, Z., He, X., Zhang, X., Wu, Y., Xing, B., Knowles, A., Shan, Q., Miller, S. I., Hojnacki, T., Ma, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00344-7 · Cited by 101
Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment
Yu, S., Wang, Y., He, P., Shao, B., Liu, F., Xiang, Z., Yang, T., Zeng, Y., He, T., Ma, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.809304 · Cited by 101
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
Ζαννίκου, Μ., Duffy, J. T., Levine, R., Seblani, M. D., Liu, Q., Presser, A., Arrieta, V. A., Chen, C. J., Sonabend, A. M., Horbinski, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006239 · Cited by 93
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González‐Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 118
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Several antigens being evaluated as candidates for anti-CRC CAR-T cell therapy have shown efficacy in CRC preclinical models, including carcinoembryonic antigen and guanylyl cyclase 2C [227,228].”
Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.
Deng, X., Gao, F., Li, N., Li, Q., Zhou, Y., Yang, T., Cai, Z., Du, P., Chen, F., & Cai, J. (2019) · PubMed Central · Cited by 74
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 84
Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
Kreidieh, M., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2020) · BioMed Research International · doi:10.1155/2020/9037217 · Cited by 68
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 68
Emerging immunotherapies for metastasis
Edwards, S. C., Hoevenaar, W. H. M., & Coffelt, S. B. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01160-5 · Cited by 62
Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors
Tolba, M. F. (2020) · International Journal of Cancer · doi:10.1002/ijc.33056 · Cited by 62
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., Zhan, T., Kraft, W. K., Sato, T., & Waldman, S. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0576-2 · Cited by 62
Self-citation
CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Li, H., Yang, C., Cheng, H., Huang, S., & Zheng, Y. (2021) · Journal of Cancer · doi:10.7150/jca.50509 · Cited by 59
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
Pagotto, S., Simeone, P., Brocco, D., Catitti, G., Bellis, D. D., Vespa, S., Pietro, N. D., Marinelli, L., Stefano, A. D., Veschi, S., et al. (2023) · Cancers · doi:10.3390/cancers15041052 · Cited by 53
New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses
Kamrani, A., Nasiri, H., Hassanzadeh, A., Ahmadian Heris, J., Mohammadinasab, R., Sadeghvand, S., Sadeghi, M., Valedkarimi, Z., Hosseinzadeh, R., Shomali, N., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01430-8 · Cited by 50
Recent advances in CAR-T cells therapy for colorectal cancer
Qin, X., Wu, F., Chen, C., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904137 · Cited by 47
Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 47
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
Jin, K., Chen, B., Liu, Y., Lan, H., & Yan, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01763-9 · Cited by 48
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., Ghanmi, A. E., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 47
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy
Ouladan, S., & Orouji, E. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02081 · Cited by 48
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Keshavarz, A., Salehi, A., Khosravi, S., Shariati, Y., Nasrabadi, N., Kahrizi, M. S., Maghsoodi, S., Mardi, A., Azizi, R., Jamali, S., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03163-w · Cited by 47
Novel antigens of CAR T cell therapy: New roads; old destination
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101079 · Cited by 45
Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients
Wang, D., Zhang, H., Xiang, T., & Wang, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762341 · Cited by 38
Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
Flickinger, J. C., Singh, J., Carlson, R. D., Leong, E., Baybutt, T. R., Barton, J. R., Caparosa, E. M., Pattison, A. M., Rappaport, J. A., Roh, J. W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001046 · Cited by 40
Self-citation
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Wang, C., & Fakih, M. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1933940 · Cited by 36
Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions
Zhu, J., Zhou, J., Tang, Y., Huang, R., Lu, C., Ke, Q., Zhou, Q., Zhang, J., Yang, X., Zhou, W., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03938-0 · Cited by 39
Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention
Yarla, N. S., Gali, H., Pathuri, G., Smriti, S., Farooqui, M., Panneerselvam, J., Kumar, G., Madka, V., & Rao, C. V. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.011 · Cited by 32
Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
Janssen, E., Subtil, B., Ortiz, F. D. L. J., Verheul, H. M. W., & Tauriello, D. V. F. (2020) · Cancers · doi:10.3390/cancers12071875 · Cited by 31
CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
Chan, L. Y., Dass, S. A., Tye, G. J., Imran, S. A. M., Zaman, W. S. W. K., & Nordin, F. (2022) · Biomedicines · doi:10.3390/biomedicines10040804 · Cited by 33
Human intestinal and circulating invariant natural killer T cells are cytotoxic against colorectal cancer cells via the perforin–granzyme pathway
Díaz‐Basabe, A., Burrello, C., Lattanzi, G., Botti, F., Carrara, A., Cassinotti, E., Caprioli, F., & Facciotti, F. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13104 · Cited by 30
Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin
Merlino, D. J., Barton, J. R., Charsar, B. A., Byrne, M. D., Rappaport, J. A., Smeyne, R. J., Lepore, A. C., Snook, A. E., & Waldman, S. A. (2019) · Brain Structure and Function · doi:10.1007/s00429-019-01949-y · Cited by 30
Self-citation
Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia
Bashir, B., Merlino, D. J., Rappaport, J. A., Gnass, E. D., Palazzo, J., Feng, Y., Fearon, E. R., Snook, A. E., & Waldman, S. A. (2019) · Human Pathology · doi:10.1016/j.humpath.2018.11.032 · Cited by 27
Self-citation
Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities
Prasad, H., Mathew, J. K. K., & Visweswariah, S. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.911459 · Cited by 26
Cell Therapy as Target Therapy against Colon Cancer Stem Cells
Garza Treviño, E. N., Quiroz Reyes, A. G., Rojas Murillo, J. A., de la Garza Kalife, D. A., Delgado Gonzalez, P., Islas, J. F., Estrada Rodriguez, A. E., & Gonzalez Villarreal, C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098163 · Cited by 24
Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies
Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 28
Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis
Lisby, A., Carlson, R. D., Baybutt, T. R., Weindorfer, M., & Snook, A. E. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.08.002 · Cited by 24
Self-citation
CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
Dezfouli, A. B., Yazdi, M., Benmebarek, M.-R., Schwab, M., Michaelides, S., Micciché, A., Geerts, D., Stangl, S., Klapproth, S., Wagner, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883694 · Cited by 23
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer
Cao, Y., Efetov, S. K., He, M., Fu, Y., Beeraka, N. M., Zhang, J., Zhang, X., Bannimath, N., & Chen, K. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00684-x · Cited by 24
Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology
Yoo, H. J., & Harapan, B. N. (2021) · Immunologic Research · doi:10.1007/s12026-021-09236-x · Cited by 25
CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
Maher, J. F., & Davies, D. M. (2023) · Cancers · doi:10.3390/cancers15041171 · Cited by 22
Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
Staudt, R. E., Carlson, R. D., & Snook, A. E. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2033057 · Cited by 21
Self-citation
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential
Entezari, A. A., Snook, A. E., & Waldman, S. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1937124 · Cited by 20
Self-citation
Interaction between gut microbiota and T cell immunity in colorectal cancer
Jing, Z., Wu, Y., Chu, J., Zhanbo, Q., Wu, X., & Han, S. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103807 · Cited by 20
The updates on metastatic mechanism and treatment of colorectal cancer
Ni, Y., Liang, Y., Li, M., Lin, Y., Zou, X., 韩芳毅, Cao, J., & Li, L. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154837 · Cited by 20
Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer
Yu, F., Wang, X., Shi, H. M., Jiang, M., Xu, J., Sun, M., Xu, Q., Addai, F. P., Shi, H., Gu, J., et al. (2020) · Tumori Journal · doi:10.1177/0300891620960223 · Cited by 19
Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cells
Qi, C., Liu, D., Liu, C., Wei, X., Ma, M., Lu, X., Tao, M., Zhang, C., Wang, X., He, T., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009960 · Cited by 18
GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer
Lisby, A., Flickinger, J. C., Bashir, B., Weindorfer, M., Shelukar, S., Crutcher, M. M., Snook, A. E., & Waldman, S. A. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1876518 · Cited by 19
Self-citation
“Hurdles race for CAR T ‐cell therapy in digestive tract cancer”
Kronig, M.-N., Wehrli, M., Salas‐Benito, D., & Maus, M. V. (2023) · Immunological Reviews · doi:10.1111/imr.13273 · Cited by 20
Does the Microbiota Composition Influence the Efficacy of Colorectal Cancer Immunotherapy?
Lin, Y., Kong, D.-X., & Zhang, Y.-N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852194 · Cited by 17
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy
Flickinger, J. C., Staudt, R. E., Singh, J., Carlson, R. D., Barton, J. R., Baybutt, T. R., Rappaport, J. A., Zalewski, A., Pattison, A. M., Waldman, S. A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00483-z · Cited by 16
Self-citation
FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective
Thirumalaisamy, R., Vasuki, S., Sindhu, S., Mothilal, T. M., Srimathi, V., Poornima, B., Bhuvaneswari, M., & Hariharan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01090-0 · Cited by 17
Recent advances and progress in immunotherapy of solid cancers
Kumar, A., Emdad, L., Das, S. K., & Fisher, P. B. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.05.004 · Cited by 15
Emerging drug targets for colon cancer: A preclinical assessment
Crutcher, M. M., Baybutt, T. R., Kopenhaver, J. S., Snook, A. E., & Waldman, S. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2039119 · Cited by 15
Self-citation
Advances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14
Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives
Bittoni, A., Sotte, V., Meletani, T., Cantini, L., Giampieri, R., & Berardi, R. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.37 · Cited by 14
Stem Cells as Therapeutic Targets in Colorectal Cancer
Zalewski, A., Snook, A. E., & Waldman, S. A. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0099 · Cited by 15
Self-citation
Chinese consensus on prevention of colorectal neoplasia (2021, S hanghai)
Fang, J.-Y. (2022) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13079 · Cited by 14
Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention
Zhang, W., Zhang, J., Liu, T., Xing, J., Zhang, H., Wang, D., & Tang, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04081-3 · Cited by 14
Pro-tumorigenic role of type 2 diabetes-induced cellular senescence in colorectal cancer
Melia, F., Udomjarumanee, P., Zinovkin, D. A., Arghiani, N., & Pranjol, M. Z. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.975644 · Cited by 14
Antibody Fragment and Targeted Colorectal Cancer Therapy: A Global Systematic Review
Ghani, S., Deravi, N., Pirzadeh, M., Rafiee, B., Gatabi, Z. R., Bandehpour, M., & Yarian, F. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210810104226 · Cited by 13
CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer
Li, M., Li, S., Zhao, R., Lv, J., Zheng, D., Qin, L., Li, S., Wu, Q., Long, Y., Tang, Z., et al. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00967-1 · Cited by 13
Translational research of new developments in targeted therapy of colorectal cancer
Yang, L., Atakhanova, N. E., Arellano, M. T. C., Mohamed, M. Y., Hani, T., Fahdil, A. A., Castillo-Acobo, R. Y., Juyal, A., Hussein, A. K., Amin, A. H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154888 · Cited by 14
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives
Mandriani, B., Pellè, E., Pezzicoli, G., Strosberg, J., Abate‐Daga, D., Guarini, A., Cives, M., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102288 · Cited by 13
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies
Wang, H., & Pan, W. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04568-0 · Cited by 12
CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy
Baybutt, T. R., Entezari, A. A., Caspi, A., Staudt, R. E., Carlson, R. D., Waldman, S. A., & Snook, A. E. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2398801 · Cited by 14
Self-citation
An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer
Rappaport, J. A., & Waldman, S. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1826304 · Cited by 12
Self-citation
Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies
Srivastava, S., Tyagi, A., Pawar, V. A., Khan, N. H., Arora, K., Verma, C., & Kumar, V. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s474659 · Cited by 12
Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions
Nakayama, I., & Shitara, K. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-471716 · Cited by 12
CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges
Khorasani, A. B. S., Sanaei, M., Pourbagheri‐Sigaroodi, A., Ghaffari, S. H., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108260 · Cited by 10
Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients
Chen, K., Huang, B., Yan, S., Xu, S., Li, K., Zhang, K., Wang, Q., Zhuang, Z., Wei, L., Zhang, Y., et al. (2020) · Aging · doi:10.18632/aging.103923 · Cited by 9
Guanylyl Cyclase C as a Diagnostic and Therapeutic Target in Colorectal Cancer
Caspi, A., Entezari, A. A., Crutcher, M. M., Snook, A. E., & Waldman, S. A. (2022) · Personalized Medicine · doi:10.2217/pme-2022-0026 · Cited by 9
Self-citation
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
Dai, Z., Fu, J., Peng, X., Tang, D., & Song, J. (2022) · Cancers · doi:10.3390/cancers14194796 · Cited by 8
Progress of research on γδ T cells in colorectal cancer (Review)
Pan, L., Zhou, Y., Kuang, Y., Wang, C., Wang, W., Hu, X., & Chen, X. (2024) · Oncology Reports · doi:10.3892/or.2024.8819 · Cited by 7
Guanylate cyclase-C Signaling Axis as a theragnostic target in colorectal cancer: a systematic review of literature
Piroozkhah, M., Aghajani, A., Jalali, P., Shahmoradi, A., Piroozkhah, M., Tadlili, Y., & Salehi, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1277265 · Cited by 7
T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments
Azizi, A. A., Pillai, M. R., & Thistlethwaite, F. C. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000562 · Cited by 7
Integration of Bulk and Single-Cell RNA-Seq Data to Construct a Prognostic Model of Membrane Tension-Related Genes for Colon Cancer
Li, J., Fu, Y., Zhang, K., & Li, Y. (2022) · Vaccines · doi:10.3390/vaccines10091562 · Cited by 7
Improving the value of molecular testing: current status and opportunities in colorectal cancer precision medicine
Li, H., Guo, L., Wang, C., Hu, X., & Xu, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0293 · Cited by 7
Gene Coexpression and miRNA Regulation: A Path to Early Intervention in Colorectal Cancer
Huang, J. C., Li, M., Huang, I.-C., Hu, J.-M., Lin, W.-Z., & Chang, Y.-T. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.207 · Cited by 6
Personalized medicine in colorectal cancer: a comprehensive study of precision diagnosis and treatment
Gila, F., Khoddam, S., Jamali, Z., Ghasemian, M., Shakeri, S., Dehghan, Z., & Fallahi, J. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2459050 · Cited by 6
Promising immunotherapeutic treatments for colon cancer
Gutiu, A. G., Zhao, L., Marrah, A. J., Maher, A. J., Voss, B., Mayberry, T. G., Cowan, B. C., Wakefield, M. R., & Fang, Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02724-2 · Cited by 7
CAR cell design strategies in solid tumors.
Wang, L., Chen, X., Zhang, L., Niu, B.-N., Li, L., Sun, Y., & Yuan, X.-L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109345 · Cited by 7

Authors: Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E.
Affiliations: Thomas Jefferson University (US)
Drexel University (US)
Corresponding author: Snook, Adam E.
ORCID: Magee, Michael S.
Abraham, Tara S.
Baybutt, Trevor R.
Flickinger, John C.
Ridge, Natalie A.
Prajapati, Priyanka
Waldman, Scott A.
Snook, Adam E.
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-04-30
Volume: 6
Issue: 5
Pages: 509-516
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-16-0362
PMC: PMC5932207
OpenAlex: W2796020321
Cited by: 143
References: 31
Citations by year: 2026: 11 · 2025: 12 · 2024: 15 · 2023: 23 · 2022: 31 · 2021: 22 · 2020: 14 · 2019: 10 · 2018: 5
FWCI: 4.78
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
The Medicine Forum (submittedVersion)
Funders: NIH (P30 CA56036, R01 CA204881, R01 CA206026, F31 CA171672)
Pennsylvania Department of Health (SAP #4100059197, SAP #4100051723)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: GUCY2C, chimeric antigen receptor T cells, CAR T-cell therapy, colorectal cancer metastasis, lung metastasis, scFv, tumor antigen targeting, intestinal epithelium, xenograft models, adoptive T cell therapy
MeSH terms: Receptors, Enterotoxin, Receptors, Chimeric Antigen, Animals, Cells, Cultured, Cytotoxicity, Immunologic, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Metastasis, Receptors, Antigen, T-Cell, T-Lymphocytes, Colorectal Neoplasms, Immunotherapy, Adoptive, Xenograft Model Antitumor Assays, Mice, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks